Tercica Files Patent Infringement Suit against Insmed & Avecia
December 21, 2004Tercica, Inc. announced on Monday the filing of a suit for patent infringement in the High Court of Justice (Chancery Division Patents Court) in the United Kingdom against Insmed Incorporated of Glen Allen, Virginia and Avecia Limited of the United Kingdom.
In the suit, Tercica is seeking an injunction, damages and declaratory relief, a press release by Tercica stated.
The suit alleges that by making, using, and selling the SomatoKine(R) product for the treatment of Growth Hormone Insensitivity Syndrome (GHIS) in the United Kingdom, the companies infringe a European (UK) patent under which Tercica holds an exclusive license.
SomatoKine(R) is a complex of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3).
"Tercica's patent portfolio consists of a broad range of patents covering both IGF-1 as well as the combination of IGF-1 and IGFBP-3," Tercica's Senior Vice President of Legal Affairs and General Counse, Stephen N. Rosenfield said.
"This case relates to the infringement of one of our patents for combining IGF-1 and IGFBP-3 for the treatment of short stature, and on October 18, 2004, we sent our first letter demanding that the infringing activities be stopped in the United Kingdom."
Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of rhIGF-1 for the treatment of short stature, diabetes and other endocrine system disorders.
Keywords
Headquarters
Add(Beijing):7th Floor,Scitech Place,22 Jianguomenwai Avenue,Beijing 100004,China
Tel: ＋86 10 5920 8888
Fax: ＋86 10 5920 8588
E-mail: mail@unitalen.com
Newsletter
Do not miss out on the latest announcements we've provided
Networking
Unitalen Mail Box ?2016 Unitalen Attorneys at Law 版權所有 集佳知識產(chǎn)權代理有限公司 京ICP備11033076號 京公網(wǎng)安備11010502020670